What problem does this paper attempt to address?

This paper aims to solve the problem of how to predict the treatment response through peripheral blood biomarkers in patients with non - small - cell lung cancer (NSCLC) during anti - PD - 1 immunotherapy. Specifically, the researchers hope to find indicators that can effectively predict the effect of immunotherapy by analyzing biomarkers in the blood, so as to help doctors develop more personalized treatment plans and improve the treatment effect of patients. ### Research Background - **Importance of the Problem**: Although immune checkpoint inhibitors (ICIs) have shown significant potential in the treatment of non - small - cell lung cancer, only a small number of patients can benefit from them in the long - term. Therefore, it is crucial to identify biomarkers that can predict the effect of immunotherapy. - **Limitations of Existing Methods**: Currently, commonly used biomarkers such as PD - L1 expression and tumor mutation burden (TMB) have problems of invasiveness and difficulty in real - time monitoring in the detection of tumor tissues. Therefore, it is particularly important to find non - invasive biomarkers that can be dynamically monitored. ### Research Objectives - **Main Objective**: Identify biomarkers that can predict treatment response by analyzing peripheral blood biomarkers of 224 NSCLC patients receiving anti - PD - 1 immunotherapy. - **Specific Objectives**: - Evaluate the correlation between different biomarkers and treatment response. - Develop a prediction tool based on a machine - learning model to predict the treatment response of patients. - Compare the differences in biomarkers among patients with different pathological types (squamous cell carcinoma and adenocarcinoma). ### Research Methods - **Research Design**: Retrospective study. - **Sample Selection**: 224 NSCLC patients receiving anti - PD - 1 immunotherapy. - **Data Collection**: 114 peripheral blood biomarkers including clinical features, blood cell counts, biochemical levels, immunoassay results and immune cell subsets. - **Data Analysis**: Use four machine - learning algorithms (logistic regression, random forest, XGBoost and LightGBM) for classification prediction, and evaluate the performance of the model through indicators such as AUC value and confusion matrix. ### Main Findings - **Predictive Ability of PD - L1 and TMB**: Patients with PD - L1 TPS ≥ 10% have a longer progression - free survival (PFS), but the predictive ability of TMB has not been statistically supported due to limited data. - **Predictive Ability of Peripheral Blood Biomarkers**: - High levels of CD4/CD8 ratio and lymphocyte percentage (LYM%) are positively correlated with effective immunotherapy. - High expression of PD - 1 on T cells, neutrophil - to - lymphocyte ratio (NLR) and monocyte - to - lymphocyte ratio (MLR) have a negative impact on the treatment effect. - High levels of ΔCEA%, CYFRA21 - 1 and lactate dehydrogenase (LDH) may indicate ineffective immunotherapy. - **Differences in Different Pathological Types**: - For adenocarcinoma patients, ΔCEA%, CD3+PD - 1+, CD4+PD - 1+ and CD4/CD8 are more important in predicting prognosis. - For squamous cell carcinoma patients, age is a more important predictive factor. ### Conclusions - **Main Conclusion**: The study successfully screened out 14 important peripheral blood biomarkers, and the detection panel composed of these biomarkers can predict the response of NSCLC patients to anti - PD - 1 immunotherapy with an accuracy of 76.3%. - **Clinical Significance**: These findings are helpful for developing personalized treatment plans, avoiding over - or under - treatment, and since peripheral blood biomarkers can be monitored in real - time, the treatment plan can be dynamically adjusted during the treatment process. ### Keywords Non - small - cell lung cancer, Immunotherapy, Machine learning, Blood biomarkers

Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer

P33.07 Peripheral CD4+ T Cell Signatures in Predicting Response to Anti-PD-1 Monotherapy for Chinese Advanced Non-Small Cell Lung Cancer Patients

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Peripheral CD4 + T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

Peripheral Blood Lymphocytes Differentiation Patterns in Responses / Outcomes to Immune Checkpoint Blockade Therapies in Non-Small Cell Lung Cancer: a Retrospective Study

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Potential biomarkers for immunotherapy in non-small-cell lung cancer

Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer

Predictive Value of the Biomarker of Peripheral Blood of Lung Carcinoma Patients Responding to PD-1 Treatment: A Real-Word Study.

1322P Development and External Validation of a Novel Four-Gene-pair Signature for Predicting Clinical Response to Anti-Pd-1 Immunotherapy of Non-Small Cell Lung Cancer

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

[Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in  Non-small Cell Lung Cancer].

Discovery of Efficacy Biomarkers for Non-Small Cell Lung Cancer with First-Line Anti-Pd-1 Immunotherapy by Data-Independent Acquisition Mass Spectrometry

EP08.01-097 Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy